VitaStem by Aubrai

Live

Aging

VitaSTEM — The first AI-enabled longevity project and inaugural IP-Token launched by Aubrai, VitaDAO’s decentralized scientific agent. After six months of deep research on public and proprietary single-cell RNA-seq and multi-omics datasets, our scientific research team analyzed more than 850,000 human hematopoietic stem cell transcriptomes from donors aged 23–91 (both male and female). This effort uncovered 100+ high-potential rejuvenation target genes and revealed critical drivers of decline such as RhoA hyperactivation, CD38 upregulation, and CCR9 downregulation. Rather than treating HSC aging as a single defect, Aubrai recognized it as convergent damage across interconnected systems, generating a comprehensive multi-modal, five-phase rejuvenation protocol targeting transcriptional stress, metabolic dysfunction, and epigenetic drift in parallel. The agent shortlisted target genes using insights from thousands of peer-reviewed publications and private data and also optimized experimental protocols to guide in vitro and upcoming pre-clinical testing. For the first time, human researchers and AI Agents collaborate as co-scientists in the creation of pioneering scientific IP.

$VITASTEM

BASE

Community Sentiment

How do you feel about VitaStem by Aubrai?

...

No trend data

Market Details

BASE

Staking Available

Updates

Feed

View @vitadao on X

Project

Market Overview

$47.8B

Global stem cell therapy market by 2032

$2.3B

Hematopoietic stem cell transplantation market by 2030

65%

Adults over 65 with age-related blood/immune dysfunction

Additional Documentation

Pitch Deck

Litepaper

Summary

We analyzed 850,000 single-cell transcriptomes of hematopoietic stem cells (HSCs) across ages and identified lead target genes for rejuvenation. This proposal aims to validate these targets in vitro using RNA-based interventions and small molecules.

Problem

Aging drives HSC dysfunction, impairing the regeneration of blood and immune cells. Current treatments lack strategies to restore youthful HSC function. Precise targets for rejuvenation remain unvalidated despite advances in scRNA-seq.

Impact

Validated interventions could reverse HSC aging, restoring regenerative capacity and immune balance. This work opens a new path in regenerative medicine, enabling multi-modal strategies to improve healthspan and combat age-related decline.

Market Overview

$47.8B

Global stem cell therapy market by 2032

$2.3B

Hematopoietic stem cell transplantation market by 2030

65%

Adults over 65 with age-related blood/immune dysfunction

Additional Documentation

Pitch Deck

Litepaper

Summary

Problem

Impact

Aubrai

AUBRAI is an on-chain AI agent accelerating longevity research. Built with Dr. Aubrey de Grey's expertise, it synthesizes papers, critiques study designs, and shares live updates about RMR2

Ashish Rajput, Ph.D.

On a mission is to catalyze life science innovations to enhance human longevity and health-span. Inspired to cure Aging and age-related diseases such as cancer, Alzheimer's and other neurodegenerative diseases in the current generation lifetime. Currently investigating the links between Aging and cancer at the cellular and molecular level. Taking academic and entrepreneurial routes to progress science and its benefits to society.

VitaDAO

Tackling aging with the power of a global community and radically extend healthy human lifespan by funding cutting-edge aging research and democratizing ownership of Intellectual Property.

Q3 2025

In-silico study

Identification of genes which have potential for in-situ HSC rejuvenation by human single cell RNA-seq data analysis

Q4 2025

In-vitro validation

Validate shortlisted target genes/proteins in in-vitro HSC cells

Q2 2026

Intervention studies

Perform gene activation/ inhibition to confirm efficacy of the intervention in human Hematopoietic stem cells

Q3 2026

Small-molecule/drug intervention

Identify small molecules that can activate/inhibit to mimic targeted interventions

Q4 2026

Pre-clinical testing

Complete additional tests such as Toxicity studies, effective dose studies, etc., in mice and platforms such as human-on-a-chip

A reference model of circulating hematopoietic stem cells across the lifespan with applications to diagnostics

https://nature.com/articles/s41591-025-03716-5

Uncovering perturbations in human hematopoiesis associated with healthy aging and myeloid malignancies at single-cell resolution

https://elifesciences.org/articles/79363

Single-cell Transcriptional Atlas of Human Hematopoiesis Reveals Genetic and Hierarchy-Based Determinants of Aberrant AML Differentiation

https://aacrjournals.org/bloodcancerdiscov/article/6/4/307/763153/Single-cell-Transcriptional-Atlas-of-Human

Single-cell RNA sequencing to track novel perspectives in HSC heterogeneity

https://stemcellres.biomedcentral.com/articles/10.1186/s13287-022-02718-1

Single-cell RNA-seq reveals changes in cell cycle and differentiation programs upon aging of hematopoietic stem cells

https://genome.cshlp.org/content/25/12/1860.full

Single Cell Transcriptomics to Understand HSC Heterogeneity and Its Evolution upon Aging

https://mdpi.com/2073-4409/11/19/3125

Tokenomics

10,000,000

Total Supply

Ignition Sale	15%
Liquidity	10%
Concentrated Liquidity	10%
VitaDAO	20%
Aubrai Agent	20%
Researcher	10%
Bio Protocol	2%
Project Treasury	13%

10,000,000

Total Supply

Ignition Sale	15%
Liquidity	10%
Concentrated Liquidity	10%
VitaDAO	20%
Aubrai Agent	20%
Researcher	10%
Bio Protocol	2%
Project Treasury	13%

Stay up to date

Get the latest community updates and find out about upcoming VitaStem by Aubrai developments